Suppr超能文献

在造血生长因子存在的情况下,长时间暴露于阿糖胞苷会优先杀死白血病克隆形成细胞而非正常克隆形成细胞。

Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.

作者信息

Van Der Lely N, De Witte T, Muus P, Raymakers R, Preijers F, Haanen C

机构信息

Department of Internal Medicine, University Hospital Nijmegen, The Netherlands.

出版信息

Exp Hematol. 1991 May;19(4):267-72.

PMID:2055291
Abstract

We investigated the cytotoxic effect of the cell cycle-specific agent cytosine arabinoside (Ara-C) on clonogenic leukemic and normal bone marrow cells. To overcome kinetic resistance and to increase cytotoxicity, the cells were exposed to Ara-C in liquid culture medium for extended time periods, that is, 5 and 10 days. Subsequently the number of surviving clonogenic cells was determined in a semi-solid assay. All cultures were stimulated with the combination of recombinant human interleukin 3 (rhIL-3), granulocyte-macrophage colony-stimulating factor (rhGM-CSF), and granulocyte colony-stimulating factor (rhG-CSF) to induce optimal cell proliferation. In comparison to normal clonogenic bone marrow cells (granulocyte-macrophage colony-forming units, CFU-GM) 5-day Ara-C exposure resulted in an equal to a slightly more effective kill of leukemic colony-forming cells (CFU-L). The Ara-C dose resulting in 50% inhibition (ID50) was 1.6 +/- 1.6 x 10(-8) M for CFU-L (n = 9) and 6.7 +/- 4.3 x 10(-8) M for CFU-GM (n = 4, p = 0.096). Prolongation of the Ara-C exposure time from 5 to 10 days increased the cytotoxicity towards the majority of the leukemic clonogenic cells (ID50: 0.8 +/- 0.6 x 10(-8) M) but not towards CFU-GM (ID50: 5.7 +/- 2.8 x 10(-8) M). Overall, significantly more leukemic clonogenic cells than normal CFU-GM were killed after 10 days of exposure to Ara-C (p = 0.039). These results indicate that leukemic clonogenic cells can be eradicated preferentially by prolonged exposure to low dosages of Ara-C in the presence of hematopoietic growth factors with relative preservation of the normal hematopoietic progenitor cells.

摘要

我们研究了细胞周期特异性药物阿糖胞苷(Ara-C)对白血病克隆形成细胞和正常骨髓细胞的细胞毒性作用。为克服动力学抗性并增强细胞毒性,将细胞在液体培养基中长时间暴露于Ara-C,即5天和10天。随后,通过半固体试验测定存活的克隆形成细胞数量。所有培养物均用重组人白细胞介素3(rhIL-3)、粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)和粒细胞集落刺激因子(rhG-CSF)联合刺激,以诱导最佳细胞增殖。与正常克隆形成骨髓细胞(粒细胞-巨噬细胞集落形成单位,CFU-GM)相比,5天的Ara-C暴露对白血病集落形成细胞(CFU-L)的杀伤效果相当或略好。导致50%抑制的Ara-C剂量(ID50)对于CFU-L为1.6±1.6×10⁻⁸ M(n = 9),对于CFU-GM为6.7±4.3×10⁻⁸ M(n = 4,p = 0.096)。将Ara-C暴露时间从5天延长至10天,增加了对大多数白血病克隆形成细胞的细胞毒性(ID50:0.8±0.6×10⁻⁸ M),但对CFU-GM没有影响(ID50:5.7±2.8×10⁻⁸ M)。总体而言,暴露于Ara-C 10天后,被杀死的白血病克隆形成细胞明显多于正常CFU-GM(p = 0.039)。这些结果表明,在造血生长因子存在的情况下,通过长时间暴露于低剂量的Ara-C可优先根除白血病克隆形成细胞,同时相对保留正常造血祖细胞。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验